GlassScriptPhysician profile
Nancy Mcalduff
NPI 1669156774
$1,746.15
in general payments reported to CMS, 2019-2025
23 companies · $879 in 2025
The $879 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $243 · 2024: $624 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.16 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $352.13 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $232.37 | 2025 | Veozah |
| Pfizer INC. | $185.84 | 2024-2025 | |
| Lundbeck LLC | $160.66 | 2023-2025 | Vyepti, Rexulti |
| Bausch Health US, LLC | $118.31 | 2024-2025 | Aplenzin, Wellbutrin |
| Alexion Pharmaceuticals, INC. | $103.68 | 2023 | Ultomiris |
| Amgen INC. | $98.17 | 2024 | Krystexxa, Repatha, Otezla |
| Abbvie INC. | $75.92 | 2024-2025 | |
| Corium, LLC | $57.59 | 2024 | Azstarys |
| Exact Sciences Corporation | $49.83 | 2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $49.44 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $32.59 | 2025 | Breztri |
| Xeris Pharmaceuticals, INC. | $31.56 | 2025 | Gvoke Hypopen |
| Paratek Pharmaceuticals, INC. | $30.44 | 2025 | Nuzyra |
| Novavax INC | $24.55 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $24.08 | 2023 | Zepbound |
| Sumitomo Pharma America, INC. | $21.21 | 2025 | Gemtesa |
| Dexcom, INC. | $19.49 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $17.65 | 2025 | |
| Glaxosmithkline, LLC. | $16.67 | 2024 | Trelegy Ellipta |
| Medtronic, INC. | $15.28 | 2024 | Closurefast |
| Resmed Corp | $14.64 | 2025 | |
| Seqirus USA INC | $14.05 | 2025 | Flucelvax, Fluad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Mcalduff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.